Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Utilities Select Sector SPDR Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Utilities Select Sector SPDR Fund trades at $45.58. Which is the better fit depends on your goals.
| ACAD | XLU | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $47.73 |
52-Week Low | $20.06 | $40.57 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XLU trades at $45.30, down 1.01% today, with a bullish technical signal supported by moving averages. The ETF provides pure exposure to US utilities, benefiting from AI-driven power demand growth. Recent news highlights utilities' role in powering AI data centers, with top holdings securing long-term clean energy agreements. Technical indicators show neutral oscillators but bullish ADX signals, with key support at $44-$45 and resistance at $46.
The outlook for XLU is positive due to structural demand growth from AI infrastructure, though valuation metrics are unavailable. Risks include interest rate sensitivity and regulatory uncertainty. Analyst sentiment is mixed, with utilities transitioning from bond proxies to growth plays amid rising power needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
